165 related articles for article (PubMed ID: 37801755)
41. Mitotic functions of poly(ADP-ribose) polymerases.
Slade D
Biochem Pharmacol; 2019 Sep; 167():33-43. PubMed ID: 30910692
[TBL] [Abstract][Full Text] [Related]
42. Small Molecule Microarray Based Discovery of PARP14 Inhibitors.
Peng B; Thorsell AG; Karlberg T; Schüler H; Yao SQ
Angew Chem Int Ed Engl; 2017 Jan; 56(1):248-253. PubMed ID: 27918638
[TBL] [Abstract][Full Text] [Related]
43. Identifying Direct Protein Targets of Poly-ADP-Ribose Polymerases (PARPs) Using Engineered PARP Variants-Orthogonal Nicotinamide Adenine Dinucleotide (NAD+) Analog Pairs.
Carter-O'Connell I; Cohen MS
Curr Protoc Chem Biol; 2015 Jun; 7(2):121-39. PubMed ID: 26344237
[TBL] [Abstract][Full Text] [Related]
44. [Poly(ADP-ribose) polymerase (PARP): physiological and pathological roles].
Makogon NV; Aleksieieva IM
Fiziol Zh (1994); 2012; 58(3):95-112. PubMed ID: 22946318
[TBL] [Abstract][Full Text] [Related]
45. Family-wide analysis of poly(ADP-ribose) polymerase activity.
Vyas S; Matic I; Uchima L; Rood J; Zaja R; Hay RT; Ahel I; Chang P
Nat Commun; 2014 Jul; 5():4426. PubMed ID: 25043379
[TBL] [Abstract][Full Text] [Related]
46. A Review of PARP-1 Inhibitors: Assessing Emerging Prospects and Tailoring Therapeutic Strategies.
Ramesh S; Almeida SD; Hammigi S; Radhakrishna GK; Sireesha G; Panneerselvam T; Vellingiri S; Kunjiappan S; Ammunje DN; Pavadai P
Drug Res (Stuttg); 2023 Nov; 73(9):491-505. PubMed ID: 37890514
[TBL] [Abstract][Full Text] [Related]
47. The role of ADP-ribose metabolism in metabolic regulation, adipose tissue differentiation, and metabolism.
Szántó M; Bai P
Genes Dev; 2020 Mar; 34(5-6):321-340. PubMed ID: 32029456
[TBL] [Abstract][Full Text] [Related]
48. PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling.
van Beek L; McClay É; Patel S; Schimpl M; Spagnolo L; Maia de Oliveira T
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066057
[TBL] [Abstract][Full Text] [Related]
49. PARG Inhibitors and Functional PARG Inhibition Models.
Sasaki Y; Hozumi M; Fujimori H; Murakami Y; Koizumi F; Inoue K; Masutani M
Curr Protein Pept Sci; 2016; 17(7):641-653. PubMed ID: 27817742
[TBL] [Abstract][Full Text] [Related]
50. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
51. PARP7 and Mono-ADP-Ribosylation Negatively Regulate Estrogen Receptor α Signaling in Human Breast Cancer Cells.
Rasmussen M; Tan S; Somisetty VS; Hutin D; Olafsen NE; Moen A; Anonsen JH; Grant DM; Matthews J
Cells; 2021 Mar; 10(3):. PubMed ID: 33799807
[TBL] [Abstract][Full Text] [Related]
52. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib.
Gravells P; Neale J; Grant E; Nathubhai A; Smith KM; James DI; Bryant HE
DNA Repair (Amst); 2018 Jan; 61():25-36. PubMed ID: 29179156
[TBL] [Abstract][Full Text] [Related]
53. PARPs and PAR as novel pharmacological targets for the treatment of stress granule-associated disorders.
Grimaldi G; Catara G; Palazzo L; Corteggio A; Valente C; Corda D
Biochem Pharmacol; 2019 Sep; 167():64-75. PubMed ID: 31102582
[TBL] [Abstract][Full Text] [Related]
54. ENPP1 processes protein ADP-ribosylation in vitro.
Palazzo L; Daniels CM; Nettleship JE; Rahman N; McPherson RL; Ong SE; Kato K; Nureki O; Leung AK; Ahel I
FEBS J; 2016 Sep; 283(18):3371-88. PubMed ID: 27406238
[TBL] [Abstract][Full Text] [Related]
55. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
56. Immunochemical analysis of poly(ADP-ribosyl)ation in HaCaT keratinocytes induced by the mono-alkylating agent 2-chloroethyl ethyl sulfide (CEES): Impact of experimental conditions.
Debiak M; Lex K; Ponath V; Burckhardt-Boer W; Thiermann H; Steinritz D; Schmidt A; Mangerich A; Bürkle A
Toxicol Lett; 2016 Feb; 244():72-80. PubMed ID: 26383632
[TBL] [Abstract][Full Text] [Related]
57. Poly(ADP-ribose): PARadigms and PARadoxes.
Bürkle A; Virág L
Mol Aspects Med; 2013 Dec; 34(6):1046-65. PubMed ID: 23290998
[TBL] [Abstract][Full Text] [Related]
58. Studying the Immunomodulatory Functions of PARP1 and PARP2 in Mouse Models of Cancer.
Lutfi N; Martínez C; Yélamos J
Methods Mol Biol; 2023; 2609():195-212. PubMed ID: 36515837
[TBL] [Abstract][Full Text] [Related]
59. Novel inhibitors of poly(ADP-ribose) polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast.
Perkins E; Sun D; Nguyen A; Tulac S; Francesco M; Tavana H; Nguyen H; Tugendreich S; Barthmaier P; Couto J; Yeh E; Thode S; Jarnagin K; Jain A; Morgans D; Melese T
Cancer Res; 2001 May; 61(10):4175-83. PubMed ID: 11358842
[TBL] [Abstract][Full Text] [Related]
60. PARPs and ADP-ribosylation in RNA biology: from RNA expression and processing to protein translation and proteostasis.
Kim DS; Challa S; Jones A; Kraus WL
Genes Dev; 2020 Mar; 34(5-6):302-320. PubMed ID: 32029452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
